Binds Specifically-identified Amino Acid Sequence Patents (Class 530/387.9)
-
Publication number: 20150110777Abstract: The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.Type: ApplicationFiled: July 11, 2014Publication date: April 23, 2015Inventors: Robin Barbour, Yue Liu
-
Publication number: 20150111231Abstract: Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP ? or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPP? contained in a biological sample.Type: ApplicationFiled: February 1, 2013Publication date: April 23, 2015Inventors: Tatsuya Takahashi, Junji Onoda, Yasunobu Yoshida, Shoji Yamane, Kouhei Nishitomi, Hidekuni Yamakawa, Akira Yamauchi, Atsushi Morita, Isao Fukuda
-
Publication number: 20150110794Abstract: This disclosure provides anti-human cytomegalovirus antibodies and methods of treatment, prophylaxis, detection, and diagnosis using the same. In another aspect, the disclosure features therapeutic, prophylactic, and/or diagnostic compositions for human cytomegalovirus infection or for a human cytomegalovirus-related disease that include a binding agent (e.g., antibody) or polynucleotide disclosed herein. In some embodiments, the composition is formulated for ocular or topical administration. The compositions can further include one or more human cytomegalovirus-neutralizing antibodies, an intravenous immunoglobulin preparation, and/or one or more antiviral compounds (e.g., ganciclovir, foscamet, cidofovir, or valganciclovir).Type: ApplicationFiled: April 30, 2013Publication date: April 23, 2015Inventors: Shuji Sato, Sean Andre Beausoleil, Wan Cheung Cheung, Roberto D. Polakiewicz
-
Publication number: 20150110798Abstract: Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FR?.Type: ApplicationFiled: October 27, 2014Publication date: April 23, 2015Inventors: Philip S. Low, Dimiter S. Dimitrov, Yang Feng, Jiayin Shen
-
Publication number: 20150110793Abstract: The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human Epiregulin-expressing cancer cells.Type: ApplicationFiled: December 28, 2012Publication date: April 23, 2015Inventors: Hirotake Shiraiwa, Keiko Esaki, Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Shigero Tamba, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Yasuko Kinoshita, Masami Suzuki, Atsuhiko Kato, Etsuko Takeiri, Eri Hashimoto, Yoshinori Watanabe
-
Publication number: 20150110786Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.Type: ApplicationFiled: March 7, 2013Publication date: April 23, 2015Inventors: Deborah Fass, Iris Grossman, Tal Ilani, Assaf Alon
-
Publication number: 20150111197Abstract: The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.Type: ApplicationFiled: July 18, 2014Publication date: April 23, 2015Applicant: INSTITUT PASTEURInventors: PHILIPPE DESPRES, ANNE-CLAIRE BREHIN, VALERIE MARECHAL, PIERRE CHARNEAU, PHILIPPE SOUQUE
-
Publication number: 20150111777Abstract: The present invention relates to compositions, methods, and kits that can be used to assess neurodegeneration associated diseases and conditions in a subject by detecting the level of TDP-43 protein in platelets. The compositions, methods, and kits are suitable for neurodegeneration associated disease diagnosis, prognosis and treatment evaluation.Type: ApplicationFiled: September 24, 2014Publication date: April 23, 2015Inventor: Abdulbaki Agbas
-
Publication number: 20150110796Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: September 30, 2014Publication date: April 23, 2015Applicant: ABLYNX N.V.Inventors: FRANCIS DESCAMPS, MARIA GONZALEZ PAJUELO, PASCAL GERARD MERCHIERS, CATELIJNE STORTELERS, PETER VANLANDSCHOOT, PHILIPPE VAN ROMPAEY, MARTINE SMIT, REGORIUS LEURS, DAVID ANDRE BAPTISTE MAUSSANG-DETAILLE
-
Publication number: 20150110791Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.Type: ApplicationFiled: May 20, 2014Publication date: April 23, 2015Applicant: GENENTECH, INC.Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
-
Publication number: 20150110792Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.Type: ApplicationFiled: November 16, 2012Publication date: April 23, 2015Inventors: Veronique Bailly, Ellen Garber, Paul D. Rennert, Nicholas Joseph Lennemann, Wendy Jean Maury, Sven Henrik Moller-Tank
-
Patent number: 9011854Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.Type: GrantFiled: August 22, 2014Date of Patent: April 21, 2015Assignee: Stemcentrx, Inc.Inventors: Robert A Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
-
Patent number: 9011856Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.Type: GrantFiled: November 6, 2012Date of Patent: April 21, 2015Assignee: UCB Pharma S.A.Inventors: David G. Winkler, Jiye Shi, John Latham
-
Patent number: 9011858Abstract: Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.Type: GrantFiled: May 15, 2013Date of Patent: April 21, 2015Assignee: ZymoGenetics, Inc.Inventors: Anthony W. Siadak, Janine M. Bilsborough, Shirley A. Rene
-
Patent number: 9012610Abstract: The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed.Type: GrantFiled: June 29, 2010Date of Patent: April 21, 2015Assignee: Hytest Ltd.Inventors: Alexey G. Katrukha, Alexander B. Postnikov, Tatiana I. Solovyeva, Alexey V. Kharitonov
-
Publication number: 20150104457Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.Type: ApplicationFiled: June 25, 2013Publication date: April 16, 2015Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
-
Publication number: 20150104409Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: ApplicationFiled: October 20, 2014Publication date: April 16, 2015Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Publication number: 20150104458Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.Type: ApplicationFiled: August 26, 2014Publication date: April 16, 2015Applicant: Biomay AGInventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Publication number: 20150104455Abstract: Compositions and methods for treating and diagnosing acute myocardial infarction are described. The invention also provides a method of treating an individual to prevent or inhibit damage to myocardial tissue from an acute myocardial infarction comprising administering to the individual an antibody to BMP-1-3, or an antibody to BMP-1-4, or a combination of an antibody BMP-1-3 and an antibody to BMP-1-4 prior to AMI.Type: ApplicationFiled: April 25, 2013Publication date: April 16, 2015Inventors: Slobodan Vukicevic, Lovorka Grgurevic, Ivo Dumic-Cule
-
Publication number: 20150104809Abstract: The present invention relates to a method for diagnosing, evaluating the prognosis of a cancer patient and evaluating the aggressiveness of a cancer. The methods comprise detecting the phosphorylation status of a Scribble protein, a fragment or variant thereof, wherein the phosphorylation status is indicative of cancer, prognosis and the aggressiveness of a cancer. In one embodiment the cancer is breast cancer.Type: ApplicationFiled: October 16, 2013Publication date: April 16, 2015Applicant: University of Essex Enterprises Ltd.Inventor: Metodi Vladimirov Metodiev
-
Publication number: 20150105315Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.Type: ApplicationFiled: October 21, 2014Publication date: April 16, 2015Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique IndustrielleInventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
-
Publication number: 20150104475Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.Type: ApplicationFiled: July 5, 2013Publication date: April 16, 2015Applicant: The Ohio State UniversityInventor: Daral John Jackwood
-
Publication number: 20150104466Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.Type: ApplicationFiled: October 16, 2013Publication date: April 16, 2015Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Teresa Compton, Adam L. Feire
-
Publication number: 20150098939Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.Type: ApplicationFiled: August 29, 2014Publication date: April 9, 2015Applicant: SANOFIInventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Carsten CORVEY, Tarik DABDOUBI, Christian ENGEL, Peter FLORIAN, Ingo FOCKEN, Katja KROLL, Jochen KRUIP, Christian LANGE, Thomas LANGER, Martin LORENZ, Vincent MIKOL, Ercole Rao, Peter WONEROW
-
Publication number: 20150098946Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.Type: ApplicationFiled: March 14, 2013Publication date: April 9, 2015Applicant: Genentech, Inc.Inventors: Sunil Bhakta, Meredith Hazen, Jo-Anne S Hongo, Jagath R Junutula, Isidro Hotzel, Yonglei Shang, Shang-Fan Yu
-
Publication number: 20150098947Abstract: Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.Type: ApplicationFiled: October 9, 2014Publication date: April 9, 2015Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philippe HAMMEL
-
Publication number: 20150098900Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: June 24, 2014Publication date: April 9, 2015Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
-
Publication number: 20150098945Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenic effects in in-vivo models.Type: ApplicationFiled: April 26, 2013Publication date: April 9, 2015Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
-
Patent number: 8999331Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.Type: GrantFiled: October 24, 2012Date of Patent: April 7, 2015Assignee: AbbVie Inc.Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yuliya Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
-
Patent number: 8999656Abstract: The present disclosure provides a method for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of PODXL protein in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount; b) comparing said sample value from step a) with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to said second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to said first group. Related uses, means and a method of treatment are also provided.Type: GrantFiled: April 26, 2012Date of Patent: April 7, 2015Assignee: Atlas Antibodies ABInventors: Karin Jirström, Mathias Uhlén, Fredrik Pontén
-
Patent number: 9000127Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.Type: GrantFiled: November 30, 2012Date of Patent: April 7, 2015Assignee: Novo Nordisk A/SInventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
-
Patent number: 8999927Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.Type: GrantFiled: April 2, 2013Date of Patent: April 7, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Qing-Rong Liu
-
Patent number: 8999651Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation.Type: GrantFiled: March 18, 2013Date of Patent: April 7, 2015Assignees: Ernst-Moritz-Arndt-Universität Greifswald, DRK Blutspendedienst West GmbHInventors: Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
-
Publication number: 20150093336Abstract: The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.Type: ApplicationFiled: March 15, 2013Publication date: April 2, 2015Inventors: Jo Van Ginderachter, Patrick De Baetselier, Nick Devoogdt, Tony Lahoutte, Damya Laoui, Kiavash Movahedi, Geert Raes, Steve Schoonooghe
-
Publication number: 20150093759Abstract: Antibodies for detecting nitration of nitrotyrosine 247 PKG-1? and antibodies for detecting nitrotyrosine 425 of PKG-1? are disclosed. Methods of detecting nitrotyrosine 247 PKG-1? and nitrotyrosine 425 of PKG-1?, and uses thereof are also disclosed for identification and diagnosis or phenotypes, pathologies, diseases and disorders associated with protein nitration of PKG-1? are also disclosed. In a preferred embodiment, one or more of the disclosed antibodies is used in the disclosed methods.Type: ApplicationFiled: September 30, 2014Publication date: April 2, 2015Inventor: Stephen M. Black
-
Publication number: 20150094454Abstract: The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides.Type: ApplicationFiled: December 3, 2014Publication date: April 2, 2015Inventors: Earl F. ALBONE, Daniel A. Soltis
-
Publication number: 20150093392Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to CDH17 with high affinity. Nucleic acid molecules encoding CDH17 antibodies, expression vectors, host cells and methods for expressing CDH17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CDH17 antibodies are also provided. Methods for detecting CDH17, as well as methods for treating carious cancers, including gastric cancer, pancreatic cancer, colon cancer and colorectal cancer, are disclosed.Type: ApplicationFiled: November 20, 2014Publication date: April 2, 2015Inventors: Jonathan Alexander TERRETT, Christian ROHLFF
-
Publication number: 20150093742Abstract: The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.Type: ApplicationFiled: June 20, 2014Publication date: April 2, 2015Inventors: Peter S. Lu, Jonathan David Garman, Michael P. Belmares, Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer
-
Publication number: 20150093389Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of a C. difficile Toxin A sequence or a C. difficile Toxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851-2710 of C. difficile Toxin A and/or residues 1853-2366 of a C. difficile Toxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/treatment/suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.Type: ApplicationFiled: April 4, 2013Publication date: April 2, 2015Applicant: The Secretary of State for HealthInventors: Clifford Shone, April Roberts, Michael Maynard-Smith
-
Publication number: 20150093390Abstract: A method of inhibiting complement activation mediated by Bb inhibitors in a subject includes administering a Bb inhibitor to the subject to inhibit at least one of Bb binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.Type: ApplicationFiled: April 2, 2013Publication date: April 2, 2015Inventor: Rekha Bansal
-
Publication number: 20150093403Abstract: The invention is directed to a isolated a canine circoviruses associated with canine respiratory and gastrointestinal disease, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to antibodies against antigens from canine circoviruses. The invention also relates to iRNAs which target nucleic acid sequences of the canine circovirus. The invention is related to methods for detecting the presence or absence of canine circoviruses in an animal. The invention is also related to immunogenic compositions for inducing an immune response against canine circoviruses in an animal.Type: ApplicationFiled: April 3, 2013Publication date: April 2, 2015Inventors: W. Ian Lipkin, Amit Kapoor, Edward J. Dubovi
-
Publication number: 20150093331Abstract: The present invention relates to biomarkers, methods and assay kits for the identification, monitoring and treatment of breast cancer.Type: ApplicationFiled: September 3, 2014Publication date: April 2, 2015Applicant: OncoLock Co., Ltd.Inventor: Yeou-Guang Tsay
-
Patent number: 8992913Abstract: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.Type: GrantFiled: June 12, 2013Date of Patent: March 31, 2015Assignee: Pfizer Inc.Inventors: Michelle M. Mader, James R. Apgar, Kevin D. Parris
-
Patent number: 8993727Abstract: Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: GrantFiled: September 22, 2011Date of Patent: March 31, 2015Assignee: Amgen Inc.Inventors: Kenneth W. Walker, Frederick W. Jacobsen, Taruna Arora
-
Patent number: 8993728Abstract: The present invention provides novel antibodies that recognize the extracellular domain of a human CLCP1 antigen; nucleic acids encoding the antibodies; vectors carrying the nucleic acids in an expressible manner; transformed cells containing the vectors; methods for producing the antibodies; diagnostic methods for cancer or prognosis of cancer, immunohistological or immunocytological assay methods, and kits for determining the expression level of CLCP1 in cells or tissues, all of which use the antibodies; pharmaceutical compositions comprising the antibodies; agents for treating or preventing CLCP1-expressing cancer; agents for inhibiting growth, migration, invasion, or metastasis of CLCP1-expressing cancer cells; immunostaining agents for staining CLCP1-expressing cancer cells; and agents for treating or preventing CLCP1-expressing tumor.Type: GrantFiled: July 16, 2009Date of Patent: March 31, 2015Assignees: Medical and Biological Laboratories Co., Ltd., Oncomics Co., Ltd.Inventors: Ken-ichiro Ono, Takashi Takahashi
-
Publication number: 20150087013Abstract: A novel gene encoding P. pastoris orotate-phosphoribosyl transferase (URA5) is disclosed. Methods for producing and selecting yeast strains capable of stable genetic integration of heterologous sequences into the host genome are also provided.Type: ApplicationFiled: December 11, 2014Publication date: March 26, 2015Inventor: Juergen H. Nett
-
Publication number: 20150086561Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: ApplicationFiled: September 25, 2014Publication date: March 26, 2015Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Robert STEPHENSON, Reyna J. SIMON, Omar NOURZAIE
-
Publication number: 20150086577Abstract: Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus Phlebovirus (family Bunyaviridae) with a proposed name of Heartland virus (HRTLV). Provided herein are nucleotide and amino acid sequences of the Phlebovirus isolates, primers and probes that specifically hybridize with the Phlebovirus isolates, and antibodies specific for the Phlebovirus proteins. Also provided are detection assays using the Phlebovirus nucleic acid molecules, proteins, probes, primers and antibodies. Further provided are recombinant Phleboviruses and their use for eliciting an immune response in a subject.Type: ApplicationFiled: March 22, 2013Publication date: March 26, 2015Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventors: Laura K. McMullan, Cynthia Goldsmith, Aubree Kelly, William L. Nicholson, Stuart T. Nichol
-
Publication number: 20150086558Abstract: Antibodies binding to junction regions between the CH4 and C?mX domains of membrane-bound IgE and uses thereof in treating IgE-mediated diseases such as allergic diseases.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Applicant: Academia SinicaInventors: Tse Wen Chang, Jiun-Bo Chen, Chien-Jen Lin, Nien-Yi Chen
-
Publication number: 20150086978Abstract: The present invention provides monoclonal antibodies that are specific for the Dengue non-structural glycoprotein NS1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including ELISA and lateral flow assays, that employ the disclosed antibodies for the early detection of Dengue virus infection. Diagnostic kits for the detection of Dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies.Type: ApplicationFiled: December 10, 2014Publication date: March 26, 2015Inventors: Syamal RAYCHAUDHURI, Raymond L. HOUGHTON, Stanislaw MORKOWSKI, Yvonne STEVENS, Mohua BOSE, James William NEEDHAM, Hongjing CHEN